Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Oppe

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 17, 2020
Health-related quality of life after traumatic brain injury: deriving value sets for the QOLIBRI-OS for Italy, The Netherlands and The United KingdomDaphne C Voormolen, Suzanne Polinder, Nicole von Steinbuechel, et al.
Pharmacoeconomics|April 17, 2020
International Valuation Protocol for the EQ-5D-Y-3LJuan M Ramos-Goñi, Mark Oppe, Elly Stolk, et al.
Pharmacoeconomics - Open|April 27, 2022
Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in CanadaElisabetta Fenu, Vasily Lukyanov, Annabel Acs, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 5, 2022
Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences?Juan M Ramos-Goñi, Anabel Estévez-Carrillo, Oliver Rivero-Arias, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|December 21, 2022
Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in FranceMark Oppe, Bogdan Muresan, Katie Chan, et al.
Arthritis Care & Research|November 12, 2015
Cost-Effectiveness Model for Evaluating New Diagnostic Tests in the Evaluation of Patients With Inflammatory Arthritis at Risk of Having Rheumatoid ArthritisJolanda J Luime, Leander R Buisman, Mark Oppe, et al.
Arthritis Research & Therapy|June 12, 2016
A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritisLeander R Buisman, Jolanda J Luime, Mark Oppe, et al.
Medical Care|December 19, 2014
Valuation and Modeling of EQ-5D-5L Health States Using a Hybrid ApproachJuan M Ramos-Goñi, Jose L Pinto-Prades, Mark Oppe, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 18, 2021
Adapting preference-based utility measures to capture the impact of cancer treatment-related symptomsKoonal K Shah, Bryan Bennett, Andrew Lenny, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 16, 2013
Validity and responsiveness of the EQ-5D and the KIDSCREEN-10 in children with ADHDClazien Bouwmans, Annemarie van der Kolk, Mark Oppe, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 17, 2020
Health-related quality of life after traumatic brain injury: deriving value sets for the QOLIBRI-OS for Italy, The Netherlands and The United KingdomDaphne C Voormolen, Suzanne Polinder, Nicole von Steinbuechel, et al.
Pharmacoeconomics|April 17, 2020
International Valuation Protocol for the EQ-5D-Y-3LJuan M Ramos-Goñi, Mark Oppe, Elly Stolk, et al.
Pharmacoeconomics - Open|April 27, 2022
Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in CanadaElisabetta Fenu, Vasily Lukyanov, Annabel Acs, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 5, 2022
Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences?Juan M Ramos-Goñi, Anabel Estévez-Carrillo, Oliver Rivero-Arias, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|December 21, 2022
Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in FranceMark Oppe, Bogdan Muresan, Katie Chan, et al.
Arthritis Care & Research|November 12, 2015
Cost-Effectiveness Model for Evaluating New Diagnostic Tests in the Evaluation of Patients With Inflammatory Arthritis at Risk of Having Rheumatoid ArthritisJolanda J Luime, Leander R Buisman, Mark Oppe, et al.
Arthritis Research & Therapy|June 12, 2016
A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritisLeander R Buisman, Jolanda J Luime, Mark Oppe, et al.
Medical Care|December 19, 2014
Valuation and Modeling of EQ-5D-5L Health States Using a Hybrid ApproachJuan M Ramos-Goñi, Jose L Pinto-Prades, Mark Oppe, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 18, 2021
Adapting preference-based utility measures to capture the impact of cancer treatment-related symptomsKoonal K Shah, Bryan Bennett, Andrew Lenny, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 16, 2013
Validity and responsiveness of the EQ-5D and the KIDSCREEN-10 in children with ADHDClazien Bouwmans, Annemarie van der Kolk, Mark Oppe, et al.
Pageof 6